Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From Acerta Pharma BV

Finance Watch: BioGeneration Ventures, Autobahn Labs Offer New Start-Up Resources

Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.

Financing Innovation

Shifting EU Treatment Paradigms In CLL

The CLL market segment in the EU will now include a first-line combination therapy of AbbVie’s venetoclax and Roche’s obinutuzumab, which has recently been approved by the European Commission.

Cancer Approvals

Janssen's Imbruvica Leads CLL Market Expansion In Europe

Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.

Market Intelligence Cancer

AZ Pushes Further Ahead In PARP Race With Lynparza/Avastin Combo

The PAOLA-1 study has shown the benefit of Lynparza for ovarian cancer patients regardless of tumor mutation status which should firm up the drug's dominance in the PARP inhibitor space.

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register